$-0.03 EPS Expected for Antares Pharma (ATRS); Orion Energy Systems, Inc. (OESX) Had 3 Bullish Analysts

November 7, 2017 - By Clifton Ray

Analysts expect Antares Pharma Inc (NASDAQ:ATRS) to report $-0.03 EPS on November, 8.They anticipate $0.01 EPS change or 25.00% from last quarter’s $-0.04 EPS. After having $-0.02 EPS previously, Antares Pharma Inc’s analysts see 50.00% EPS growth. The stock increased 0.53% or $0.01 during the last trading session, reaching $1.89. About shares traded. Antares Pharma Inc (NASDAQ:ATRS) has risen 207.14% since November 7, 2016 and is uptrending. It has outperformed by 190.44% the S&P500.

Among 5 analysts covering Orion Energy Systems (NASDAQ:OESX), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Orion Energy Systems had 9 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Hold” on Wednesday, September 2. H.C. Wainwright maintained Orion Energy Systems, Inc. (NASDAQ:OESX) on Friday, May 26 with “Buy” rating. The stock of Orion Energy Systems, Inc. (NASDAQ:OESX) has “Buy” rating given on Monday, July 18 by Rodman & Renshaw. On Thursday, October 5 the stock rating was maintained by Roth Capital with “Hold”. Roth Capital maintained Orion Energy Systems, Inc. (NASDAQ:OESX) rating on Friday, June 9. Roth Capital has “Hold” rating and $1.3000 target. The firm earned “Buy” rating on Tuesday, August 4 by Roth Capital. The rating was downgraded by TH Capital to “Buy” on Tuesday, August 4. H.C. Wainwright maintained the stock with “Buy” rating in Monday, August 7 report. The firm has “Buy” rating given on Friday, June 9 by H.C. Wainwright. See Orion Energy Systems, Inc. (NASDAQ:OESX) latest ratings:

05/10/2017 Broker: Roth Capital Rating: Hold New Target: $1.0 Maintain
07/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.5000 Maintain
09/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.0000 Maintain
09/06/2017 Broker: Roth Capital Rating: Hold New Target: $1.3000 Maintain
26/05/2017 Broker: H.C. Wainwright Rating: Buy Maintain

The stock decreased 2.21% or $0.02 during the last trading session, reaching $0.89. About shares traded. Orion Energy Systems, Inc. (NASDAQ:OESX) has risen 9.45% since November 7, 2016 and is uptrending. It has underperformed by 7.25% the S&P500.

Orion Energy Systems, Inc. is a designer and maker of lighting platforms. The company has market cap of $25.73 million. The Firm researches, develops, designs, makes, markets, sells and implements energy management systems consisting primarily of commercial and industrial interior and exterior lighting systems, and related services. It currently has negative earnings. The Firm operates through three divisions: Orion U.S.

Investors sentiment decreased to 0.76 in 2017 Q2. Its down 0.64, from 1.4 in 2017Q1. It fall, as 8 investors sold Orion Energy Systems, Inc. shares while 9 reduced holdings. 5 funds opened positions while 8 raised stakes. 12.85 million shares or 1.17% more from 12.70 million shares in 2017Q1 were reported. Optimum Invest Advisors, Illinois-based fund reported 40,000 shares. Creative Planning invested in 10,000 shares. Morgan Stanley accumulated 0% or 1,307 shares. Bank Of America De owns 72,699 shares for 0% of their portfolio. Guggenheim Cap Ltd Liability Corp invested in 13,381 shares or 0% of the stock. State Street Corp has invested 0% in Orion Energy Systems, Inc. (NASDAQ:OESX). Renaissance Technologies Ltd Company holds 805,000 shares. North Star Investment Mngmt reported 2.83M shares. Tower Cap Limited Liability Corporation (Trc) has invested 0% in Orion Energy Systems, Inc. (NASDAQ:OESX). Adirondack Rech & Mgmt holds 0.66% or 1.33 million shares in its portfolio. Barclays Public Limited reported 2,737 shares stake. Blackrock has invested 0% in Orion Energy Systems, Inc. (NASDAQ:OESX). Firsthand Inc, a California-based fund reported 14,000 shares. Dimensional Fund Advsrs Limited Partnership has 455,065 shares. Moreover, Bessemer Grp has 0% invested in Orion Energy Systems, Inc. (NASDAQ:OESX).

Since June 13, 2017, it had 4 insider buys, and 0 insider sales for $21,289 activity. The insider Otten Anthony L. bought 1,500 shares worth $2,055. $6,742 worth of stock was bought by Altschaefl Michael W on Thursday, June 15. 4,000 Orion Energy Systems, Inc. (NASDAQ:OESX) shares with value of $5,560 were bought by Meade Marc.

Investors sentiment decreased to 2.07 in 2017 Q2. Its down 0.80, from 2.87 in 2017Q1. It fall, as 16 investors sold Antares Pharma Inc shares while 14 reduced holdings. 36 funds opened positions while 26 raised stakes. 53.64 million shares or 13.47% more from 47.27 million shares in 2017Q1 were reported. Natl Bank Of Ny Mellon Corp owns 525,506 shares. Renaissance Technology Limited Liability Corp holds 3.46 million shares or 0.01% of its portfolio. Deutsche National Bank & Trust Ag accumulated 1.00 million shares or 0% of the stock. Moreover, National Bank Of America Corp De has 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 7,424 shares. Rhumbline Advisers holds 146,925 shares. Prudential Fin owns 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 14,590 shares. Schwab Charles Investment Management invested in 533,576 shares. Creative Planning accumulated 26,500 shares or 0% of the stock. Gru One Trading L P accumulated 1,800 shares. Perkins Cap Mgmt Inc holds 0.04% or 10,000 shares in its portfolio. Geode Cap Mngmt Lc, Massachusetts-based fund reported 1.19M shares. Credit Suisse Ag holds 0% or 30,444 shares. Principal Gp Inc holds 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 26,298 shares. Jw Asset Management Llc accumulated 1.67 million shares. Moreover, Arrowstreet Partnership has 0% invested in Antares Pharma Inc (NASDAQ:ATRS).

Since June 9, 2017, it had 1 insider purchase, and 0 insider sales for $363,272 activity. 130,000 shares valued at $363,272 were bought by Powell Fred M on Friday, June 9.

Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has market cap of $295.61 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.